Takeda Pharmaceutical Co., Ltd. et al v. Impax Laboratories, Inc.,

Filing 308

REDACATED ORDER re 167 MOTION for Partial Summary Judgment filed by Impax Laboratories, Inc.,, 169 Document E-Filed Under Seal,,, filed by Impax Laboratories, Inc.,, 203 Document E-Filed Under Seal, filed by Takeda Pha rmaceuticals America, Inc., Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals LLC, 174 MOTION for Summary Judgment Of Infringement of the '058, '276, and '971 Patents [PUB LIC VERSION] filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals LLC. Signed by Judge Joseph C. Spero on 04/08/13. (klhS, COURT STAFF) (Filed on 5/30/2013)

F ILE D
APR X 8 2013

2

RICHARD W. WIEKING

3

UNITED STATES DISTRICT COURTCLERK. U.S. DISTRICT COURT
N
ORTHERN DISTRICT OF CALIFORNIA
NORTHERN DISTRICT OF CALIFORNIA

4

5
6
7

TAKEDA PHARMACEUTICAL CO., LTD.,

8

et al.,
Plaintiffs,

9

v.

10

11

ro

t::
;:j

·a

.....

Defendant.

12

o..B
();.::::

IMP AX LAB ORATORIES, INC.,

13

Case No.C-11-0 161 0 JCS

ORDER RE SUMMARY J UDGMENT
MOTIONS [Docket Nos. 167, 174 (redacted
publicly filed versions); 169, 203 (sealed
versions)]
FILED UNDER SEAL

!REDACTED vEJM

y

ell

.....

-~ ()

.1::::1'+-<
-~ 0
Qt)

14

I.

INTRODUCTION
Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals North America, Inc., Takeda

·.s

15

clio
'"0 8
Cl)
Cl)

16

Pharmaceuticals LLC, and Takeda Pharmaceuticals America, Inc. (hereinafter, referred to

17

collectively as "Takeda") initiated this action under 35 U.S.C. § 271 and the Declaratory

z

18

Judgment Act, 28 U.S.C. §§ 2201,2202, in response to Abbreviated New Drug Applications

19

("ANDA") 202-576 of Defendant lmpax Laboratories, Inc. ("lmpax") seeking approval of the

20

United States Food and Drug Administration ("FDA") to manufacture and sell 30-mg and 60-mg

21

generic versions of Takeda's drug DEXILANT (dexlansoprazole) ("the ANDA products").

22

Takeda alleges that Impax's ANDA products infringe U.S. Patent No. 6,462,058 ("the '058

23

Patent"), U.S. Patent No. 6,664,276 ("the '276 Patent"), U.S. Patent No. 6,939,971 ("the '971

24

Patent") and U.S. Patent No. 7,790,755 ("the '75 5 Patent") (collectively, "the Asserted Patents").

~

..... ......
ell rn

· '€
a
oo

25
26
1

27
28

In its complaint, Takeda also alleged that lmpax's ANDA products infringed U.S. Patent No.
7,285,668 ("the '668 Patent"). However, on November 28, 2012, the Court dismissed Takeda's
claims based on the '668 Patent, as well as Impax's counterclaims based on that patent, pursuant
to the stipulation of the parties. See Docket No. 171.

1